Artelo Biosciences ARTL 深 滬
等待開盤 11-04 09:30:00 美东时间
2.40
+0.230
+10.60%
華盛通- 最 高2.405
- 今 開2.14
- 成交量 3.11万股
- 最 低 2.12
- 昨 收 2.17
- 總市值 131.47万
- 52周最高 179.1891
- 市盈率 靜 --
- 換手率 5.68%
- 52周最低 2.05
- 委 比 -92.90%
- 總股本 54.78万
- 歷史最高 12150.00
- 量 比 0.77
- 振 幅 13.13%
- 歷史最低 2.05
- 每 手 1
- 風險率 20.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Bioscience To Present Data On ART26.12 Program At IASP 2026 World Congress On Pain, October 26–30; Growing Body Of Data Supports ART26.12’s Potential As A Novel, Non-Opioid Treatment For Pain Ahead Of Planned Multiple Ascending Dose Study
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that Professor Saoi...
10-26 19:58
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Artelo Biosciences' ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, is being presented at the IASP 2026 World Congress on Pain. ART26.12 shows promise as a novel, non-opioid treatment for pain, with data demonstrating efficacy in chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and other chronic pain conditions. Early clinical results indicate a favorable safety profile and predictable pharmacokineti...
10-26 11:55
Artelo Biosciences Addresses Nasdaq Listing Compliance Uncertainty
Artelo Biosciences ( ($ARTL) ) has provided an update. On July 22, 2026, the SE...
10-10 05:51
CNR1（CB1）：曾因"自杀风险"沉寂，如今重回减重赛道
（来源：药研网） 利莫那班退市之后，CB1沉寂了近二十年。如今，这个靶点上有了新进展。 2008年，赛诺菲的利莫那班（rimonabant，商品名Acompl...
09-24 13:44
Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?
Artelo Biosciences, Inc. (NASDAQ:ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity. The patent submission protects ART27.13 bot...
09-24 01:46
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.
09-24 01:23
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
09-16 22:58
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
<p>Artelo Biosciences announced promising results from a study of ART27.13, an oral, once-daily dual cannabinoid receptor agonist, in obese mice. ART27.13 alone reduced body weight by approximately 20%, matching the weight loss achieved with semaglutide. When combined with semaglutide, weight loss doubled to around 40%. The study suggests ART27.13 may act as a "metabolic regulator," selectively modifying weight and fat loss in obese animals while...
09-16 11:30
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that CEO Gregory D. Gorgas will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York City. The company’s presentation will be available on September 11, 2026, at 7:00 a.m. ET, and can be accessed via the provided link. Management will also engage in one-on-one meetings with investors during the conference. Artelo focuses on developing th...
09-08 13:00
Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock sp...
08-27 20:03
